The trial sponsored by Bioaraba Health Research Institute aims to evaluate a triple intervention strategy for glycemic control in prediabetic patients, a significant market segment given the rising prevalence of diabetes globally. With an estimated 50% of prediabetics progressing to diabetes within five years, effective preventive strategies are critical. The intervention combines dietary advice and physical activity, which may position it favorably against pharmacological treatments. The results could support the development of lifestyle-based therapeutic guidelines, potentially leading to partnerships with healthcare providers and insurers focused on preventive care. The competitive landscape includes both lifestyle interventions and emerging diabetes therapeutics, necessitating a thorough diligence process to assess market entry strategies and reimbursement pathways.